Search Results
Your search for ,foR matches 32806 pages
Showing 25751 - 25800Focus on the Georgia Society of Clinical Oncology
With a roster of over 600 members that includes community and institutional oncologists, administrators, registered nurses, and patient navigators, the Georgia Society of Clinical Oncology (GASCO) is one of ASCO’s largest State Affiliates. Founded in 1986, the Atlanta-based Society is active in...
Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was approved by...
Oncology Meetings
June 2nd International Breakthrough Breast Cancer Conference– Triple Negative Breast CancerJune 26-28 • London, United KingdomFor more information: www.breakthroughconference.org.uk MASCC/ISOO 2013 International Cancer Care SymposiumJune 27-29 • Berlin, GermanyFor more information: mascc.kenes.com ...
Partnership Seeks to Accelerate Development of Innovative Therapies
The Leukemia & Lymphoma Society (LLS) recently joined the Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. This Blood Cancer Research Partnership (BCRP) will...
Orphan Drug Status Granted for Novel Targeted Therapy to Treat Rare Hematologic Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Stemline Therapeutics’ SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive hematologic malignancy for which there is no effective treatment. SL-401 also has Orphan Drug...
Vitamin D and Cancer: A Uniform Dose Is Unlikely to Fit All Patients
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance S. Rockefeller Chair in Integrative Medicine at Memorial Sloan-Kettering Cancer Center, New York. The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center...
How to Recognize and Manage Hand-Foot Syndrome Due to Capecitabine or Doxorubicin
Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that...
Dabrafenib for Unresectable or Metastatic Melanoma with BRAF V600E Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, dabrafenib (Tafinlar) was approved for ...
Improving Treatment and Care for Patients with Primary Brain Cancers
Despite advances in neuroimaging, the development of focused radiation therapy, and more effective chemotherapy, life expectancy for patients with primary malignant tumors of the brain and spinal cord remains stubbornly low at between 15 and 18 months. However, there are significant advances on the ...
Treating Both the Physical and Psychological Symptoms of Cancer
A growing number of people with cancer are being treated on an outpatient basis. At the Herbert Irving Comprehensive Cancer Center of New York-Presbyterian Hospital/Columbia University Medical Center in New York, to ensure that the psychosocial and psychiatric needs of these patients were being...
Celebrations Nationwide Recognize Cancer Survivorship in June
Among the celebrations held nationwide recognizing survivorship day in June, there was a special program held on June 10, 2013, at Memorial Sloan-Kettering Cancer Center in New York. Mary McCabe, RN, MS, Director, Survivorship Program, at MSKCC, moderated the program. The evening celebration...
SIDEBAR: New Insights into Treatment for Two Types of Leukemia
The combination of functional and genomic screens has allowed us to accelerate the identification of oncogenes, as well as drug sensitivity that corresponds with those oncogenes. In the present study, we found that CSF3R mutations define chronic neutrophilic leukemia and atypical chronic myeloid...
Identification of Oncogenic Mutations in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
Among the hematologic cancers for which molecular causes remain unclear are chronic neutrophilic leukemia and atypical (BCR-ABL1–negative) chronic myeloid leukemia. Both disorders currently are diagnosed on the basis of neoplastic expansion of granulocytic cells and exclusion of genetic factors...
Similar Short-term Outcomes with Laparoscopic vs Open Surgery for Rectal Cancer
As recently reported in Lancet Oncology by Martijn H.G.M. van der Pas, MD, of VU University Medical Center, Amsterdam, and colleagues, the phase III COLOR II trial has shown that laparoscopic surgery can produce similar safety outcomes, resection margins, and completeness of resection compared with ...
College of American Pathologists Issues Statement on Supreme Court Gene Patent Decision
In a statement released earlier this month, the College of American Pathologists applauded the unanimous Supreme Court decision invalidating the patents held by Myriad Genetics on the BRCA1 and BRCA2 genes, calling the decision “a victory for patients and for science.” The College of American...
No Survival Benefit of ERCC1 and RRM1 Expression-based Chemotherapy in Patients with Advanced NSCLC
A trial reported by Gerold Bepler, MD, PhD, of Karmanos Cancer Institute, Detroit, and colleagues in Journal of Clinical Oncology assessed whether chemotherapy selected on the basis of in situ ERCC1 and RRM1 protein levels could improve outcomes in patients with advanced non–small cell lung cancer...
Thirty Years of Advancing Cancer Research and Care
In the last 30 years, discoveries made through research have fueled great improvements in cancer prevention, treatment, and care. Major progress against cancer has been made, and steady investment both in scientific studies and in the careers of researchers has led to transformations in how doctors ...
ASCO's Guideline on Fertility Preservation
Direct your patients to www.cancer.net/whattoknow so they can learn about ASCO’s recent guideline on fertility preservation, including what the recommendations mean for patients and a list of questions to ask the doctor. In addition, patients can view an infographic on ASCO’s recommendations for...
ASCO Issues Guideline Update and Videos on Fertility Preservation
ASCO recently issued an update to its guideline on fertility preservation for people living with cancer, as well as two videos jointly produced with the LIVESTRONG Foundation. Both the guideline and videos are intended to raise awareness and understanding of this important area of cancer care....
Journal of Clinical Oncology Fosters the Development of Early-career Researchers through Support of Conquer Cancer Foundation Young Investigator Awards
The Conquer Cancer Foundation of the American Society of Clinical Oncology is dedicated to funding breakthrough research and sharing cutting-edge knowledge, and the Journal of Clinical Oncology (JCO) shares this commitment: It is ranked as the most widely read oncology journal worldwide, with a...
In Memoriam: ASCO Remembers Founding Member Jane Cooke Wright, MD
Earlier this year, ASCO and the oncology community at large lost a true pioneer, mentor, and renowned researcher. It is with great sadness that we mark the passing of Jane Cooke Wright, MD, one of seven founding members of ASCO—the only woman among the founders—and the Society’s first...
Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Future Cancers by More than Half
A study examining trends in x-ray computed tomography (CT) use in children in the United States has found that reducing unnecessary scans and lowering the doses for the highest-dose scans could lower the overall lifetime risk of future imaging-related cancers by 62%. The research was published...
National Institutes of Health Issues Projected Impact of Sequestration on Programs
Earlier this month, the National Institutes of Health (NIH) released its updated projections of reductions in programs due to the deficit-budget mechanism known as sequestration, which took effect on March 1, 2013. The sequestration law requires NIH to cut 5%, or $1.55 billion, of its fiscal year...
Mitigating the Anxiety over Tumor Heterogeneity
This collaborative study with Foundation Medicine (Cambridge, Massachusetts), using very sensitive deep sequencing, partially mitigates some of the anxiety generated by the identification of tumor heterogeneity. While our data in lung cancer confirm that such heterogeneity exists, they also...
Study Shows High Concordance of Recurrent Somatic Alterations in Primary and Matched Metastatic NSCLC
In a study reported in Journal of Clinical Oncology, Stéphane Vignot, MD, of Institut National de la Santé et de la Recherche Medicale (INSERM) Unit 981, Paris, and Gustave Roussy Institute, Villejuif, France, and colleagues used next-generation sequencing to identify somatic alterations in...
KRAS Status Not Associated with Survival in Pooled Adjuvant Therapy Trials in Early-stage Lung Cancer
KRAS mutations have been reported in approximately 30% of lung adenocarcinomas. They occur most frequently in codons 12 and 13 in non–small cell lung cancer (NSCLC), and are most common in cancer in smokers and in nonsquamous NSCLC. Some data suggest that KRAS mutation is associated with poorer...
SGX942 Gets Fast Track Status for Treatment of Oral Mucositis
The FDA has granted fast track designation to the SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in patients with head and neck cancer. SGX942 is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability ...
FDA Approves Two Drugs, Companion Diagnostic Test for Advanced Skin Cancer
The U.S. Food and Drug Administration (FDA) recently approved two new drugs, dabrafenib (Tafinlar) and trametinib (Mekinist), for patients with advanced or unresectable melanoma. Dabrafenib, a BRAF inhibitor, is approved to treat patients with melanoma whose tumors express the BRAF V600E gene...
ASTRO to Award Society's Highest Honor to Three Physicians and Researchers
The American Society for Radiation Oncology (ASTRO) will award Amato J. Giaccia, PhD, Radhe Mohan, PhD, FASTRO, and Prabhakar Tripuraneni, MD, FASTRO, with the Society’s highest honor—the ASTRO Gold Medal. The 2013 awardees will receive the ASTRO Gold Medal during the society’s 55th Annual Meeting...
Radiation-sparing Dose-adjusted EPOCH-Rituximab for Primary Mediastinal B-cell Lymphoma
Tumor control is frequently not achieved with standard immunochemotherapy in patients with primary mediastinal B-cell lymphoma, requiring consolidation with mediastinal radiotherapy. However, radiotherapy is associated with serious late adverse effects and is still associated with disease...
Expert Point of View: Carol Aghajanian, MD
Commenting on these results, Carol Aghajanian, MD, Chief of the Gynecologic Medical Oncology Service at Memorial Sloan-Kettering Cancer Center, New York, said, “There is currently no standard of care for maintenance therapy. Evidence continues to mount that targeting angiogenesis is important in...
Pazopanib Maintenance Therapy Extends Progression‑free Survival in Patients with Ovarian Cancer
Maintenance therapy with the targeted therapy pazopanib (Votrient) extended progression-free survival in women with ovarian cancer who were disease-free following initial treatment with surgery and chemotherapy, according to results of a phase III trial presented at the 49th Annual Meeting of...
ASCO Joins a Global Alliance to Enable Responsible Sharing of Genomic and Clinical Data
ASCO has joined more than 70 leading health care, research, and disease advocacy organizations from around the world in taking the first steps to form an international alliance dedicated to enabling secure sharing of genomic and clinical data. The cost of genome sequencing has fallen one-million...
Brian Druker, MD, and Charles Sawyers, MD, Receive 2013 Taubman Prize for Excellence in Translational Medical Science
Brian Druker, MD, of Oregon Health & Science University in Portland, and Charles Sawyers, MD, of Memorial Sloan-Kettering Cancer Center in New York, will share the 2013 Taubman Prize for Excellence in Translational Medical Science. The $100,000 prize is given by the A. Alfred Taubman Medical...
Expert Point of View: Andrew Seidman, MD
This study shows us that less can be more in the sentinel lymph node era. We can avoid complete axillary resection. As a medical oncologist, I have learned that less can be more in many settings. As a result of this study, I will be able to reassure my patients that radiation therapy to the axilla...
Axillary Radiotherapy: New Standard of Care in Node-positive Breast Cancer?
Radiotherapy to the axilla may replace axillary lymph node dissection for local tumor control in selected patients with sentinel node–positive breast cancer, sparing many patients lymphedema, according to the final results of the European Organisation for Research and Treatment of Cancer (EORTC)...
FDA Approves New Silicone Gel-filled Breast Implant
The FDA recently approved the MemoryShape Breast Implant for breast augmentation in women at least 22 years old and for breast reconstruction in women of any age. The MemoryShape Breast Implants are manufactured by Mentor Worldwide LLC. The FDA’s approval is based on 6 years of data from 955 women...
Expert Point of View: Ann Partridge, MD
This study showed that 10 years of adjuvant tamoxifen reduced the risk of late recurrence in hormone receptor-positive breast cancer, which is a major problem. The study also showed that ‘patience is a virtue’,” stated formal discussant Ann Partridge, MD, Director of the Adult Survivorship Program...
Study Confirms 10 Years of Adjuvant Tamoxifen Is Superior to 5 Years
The landmark aTTom study showed that 10 years of adjuvant tamoxifen is superior to 5 years of tamoxifen in reducing the risk of breast cancer recurrence or death but that the full survival benefits of extended treatment do not emerge until after the 10 years of treatment. These findings, which were ...
Expert Point of View: Lynn Mara Schuchter, MD and Michael A. Davies, MD, PhD
Lynn Mara Schuchter, MD, the C. Willard Robinson Professor of Hematology-Oncology and Program Leader of the Melanoma Program at Abramson Cancer Center of the University of Pennsylvania, Philadelphia, commented at a press briefing that the study “will ultimately be practice-changing.” She noted,...
MEK Inhibitor Improves Outcomes in Metastatic Uveal Melanoma
For the first time, a drug has proven effective in the treatment of uveal (ocular) melanoma that has metastasized, according to a randomized multicenter phase II study presented at the 2013 ASCO Annual Meeting.1 “This study is the first to demonstrate an improved clinical outcome with any systemic...
ASCO President Clifford Hudis, MD, on the 2013 ASCO Annual Meeting
This year’s ASCO Annual Meeting was really exciting in two specific ways. First, we saw the development of high-tech novel therapies and combinations that effectively manipulate the immune system and extend survival in historically difficult-to-treat diseases, like metastatic melanoma (eg,...
Expert Point of View: Ezra Cohen, MD
“These patients finally have options,” commented the DECISION trial’s discussant at the ASCO Plenary Session, Ezra Cohen, MD, Associate Professor of Medicine and Associate Director for Education at the University of Chicago Comprehensive Cancer Center. He further noted that differentiated thyroid...
Sorafenib Halts Disease Progression in Metastatic Differentiated Thyroid Cancer
For the first time in decades, a drug has halted disease progression in treatment-resistant differentiated thyroid cancer, according to the results of a phase III study presented at the 2013 ASCO Annual Meeting.1 No new drugs have been approved for differentiated thyroid cancer in 40 years, but...
Simple Rapid Vinegar Test Cuts Cervical Cancer Death Rates by One-third in Rural India
In the era of personalized medicine for cancer care, it was both surprising and encouraging to hear about a simple low-tech intervention delivered by women in the community that cut the rate of death from cervical cancer in India by about one-third. The intervention, a simple visual inspection...
Expert Point of View: Gottfried Konecny, MD
Formal discussant Gottfried Konecny, MD, Associate Professor of Medicine, David Geffen School of Medicine at UCLA, also viewed the study as a game changer. He cited the strengths of the study, including its design, randomization with stratification, P values adjusted for multiple testing, and the...
Practice-changing Study Shows Survival Benefit for Antiangiogenesis in Advanced Cervical Cancer
The addition of bevacizumab (Avastin) to chemotherapy prolongs overall survival in women with metastatic cervical cancer compared with chemotherapy alone, according to the results of a randomized phase III study presented at the Plenary Session of the ASCO Annual Meeting.1 Women on the...
It’s Déjà Vu All Over Again
Yogi Berra offered the comment “It’s déjà vu all over again” when he witnessed Mickey Mantle and Roger Maris repeatedly hitting back-to-back home runs in the early 1960s. His pithy remark neatly summarizes my reaction when I read the article, “Dose-Adjusted EPOCH-Rituximab Therapy in Primary...
Financial Revamping of Medical Education
The American medical education system was in a state of crisis in 1910 when Abraham Flexner published his treatise, Report on Medical Education in the United States and Canada (Carnegie Foundation Bulletin Number Four).1 A century later, we face another crisis in medical education—not in terms of...
SIDEBAR: GM-CSF plus Ipilimumab: Ready to Use in the Clinic?
Lynn Mara Schuchter, MD, the C. Willard Robinson Professor of Hematology-Oncology and Program Leader of the Melanoma Program at Abramson Cancer Center of the University of Pennsylvania, Philadelphia, commented on the wealth of promising agents now dotting the formerly barren landscape for...
